BR112015016817A8 - métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica - Google Patents

métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica Download PDF

Info

Publication number
BR112015016817A8
BR112015016817A8 BR112015016817A BR112015016817A BR112015016817A8 BR 112015016817 A8 BR112015016817 A8 BR 112015016817A8 BR 112015016817 A BR112015016817 A BR 112015016817A BR 112015016817 A BR112015016817 A BR 112015016817A BR 112015016817 A8 BR112015016817 A8 BR 112015016817A8
Authority
BR
Brazil
Prior art keywords
saccharide
pharmaceutical composition
conjugate
saccharide derivative
derivative
Prior art date
Application number
BR112015016817A
Other languages
English (en)
Other versions
BR112015016817A2 (pt
BR112015016817B1 (pt
Inventor
Berti Francesco
Hu Qi-Ying
Adamo Roberto
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112015016817A2 publication Critical patent/BR112015016817A2/pt
Publication of BR112015016817A8 publication Critical patent/BR112015016817A8/pt
Publication of BR112015016817B1 publication Critical patent/BR112015016817B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Abstract

“métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica” a invenção fornece novos derivados de sacarídeo, conjugados, e métodos para fabricar os derivados e conjugados.
BR112015016817-5A 2013-01-15 2014-01-13 métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica BR112015016817B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
GB1300707.5 2013-01-15
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (3)

Publication Number Publication Date
BR112015016817A2 BR112015016817A2 (pt) 2017-07-11
BR112015016817A8 true BR112015016817A8 (pt) 2019-10-29
BR112015016817B1 BR112015016817B1 (pt) 2020-11-10

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016817-5A BR112015016817B1 (pt) 2013-01-15 2014-01-13 métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica

Country Status (16)

Country Link
US (2) US11135300B2 (pt)
EP (1) EP2945641B1 (pt)
JP (3) JP6719209B2 (pt)
CN (1) CN105377282B (pt)
BR (1) BR112015016817B1 (pt)
CA (1) CA2897348C (pt)
CY (1) CY1122822T1 (pt)
DK (1) DK2945641T3 (pt)
ES (1) ES2774729T3 (pt)
GB (1) GB201300707D0 (pt)
HR (1) HRP20200351T1 (pt)
LT (1) LT2945641T (pt)
PL (1) PL2945641T3 (pt)
PT (1) PT2945641T (pt)
SI (1) SI2945641T1 (pt)
WO (1) WO2014111344A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
SG11201807430WA (en) * 2016-03-04 2018-09-27 Euglena Co Ltd Antiviral agent and antiviral food
CA3048981A1 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US20210033617A1 (en) * 2018-02-05 2021-02-04 University Of Miyazaki Cell labeling agent and cell labeling kit
JP6815561B2 (ja) 2018-06-14 2021-01-20 持田製薬株式会社 新規な架橋アルギン酸
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
CA3221074A1 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526153A (ja) * 2002-03-26 2005-09-02 カイロン ソチエタ ア レスポンサビリタ リミタータ 水中において改善された安定性を持つ修飾糖
JP2008518953A (ja) * 2004-11-01 2008-06-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 連鎖球菌修飾多糖類およびそれらの使用法
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP2222341B1 (en) * 2007-11-21 2015-02-25 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
CA2785410A1 (en) * 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
EP3604264A1 (en) 2010-04-27 2020-02-05 SynAffix B.V. Fused cyclooctyne compounds
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2621905B1 (en) 2010-09-27 2017-04-12 University Of Georgia Research Foundation, Inc. Methods including latent 1,3-dipole-functional compounds and materials prepared thereby
US20120208722A1 (en) * 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
PL2721045T3 (pl) * 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
WO2013078562A2 (en) * 2011-12-01 2013-06-06 Angiochem Inc. Targeted enzyme compounds and uses thereof
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Also Published As

Publication number Publication date
DK2945641T3 (da) 2020-03-09
GB201300707D0 (en) 2013-02-27
US20210268116A1 (en) 2021-09-02
CN105377282A (zh) 2016-03-02
JP2020114839A (ja) 2020-07-30
CY1122822T1 (el) 2021-05-05
BR112015016817A2 (pt) 2017-07-11
CN105377282B (zh) 2020-07-17
LT2945641T (lt) 2020-02-25
CA2897348A1 (en) 2014-07-24
JP2016506905A (ja) 2016-03-07
BR112015016817B1 (pt) 2020-11-10
US11135300B2 (en) 2021-10-05
US20160166704A1 (en) 2016-06-16
PT2945641T (pt) 2020-03-26
WO2014111344A1 (en) 2014-07-24
ES2774729T3 (es) 2020-07-22
SI2945641T1 (sl) 2020-03-31
JP2019073528A (ja) 2019-05-16
EP2945641A1 (en) 2015-11-25
JP7036854B2 (ja) 2022-03-15
JP6719209B2 (ja) 2020-07-08
PL2945641T3 (pl) 2020-06-15
CA2897348C (en) 2022-09-27
EP2945641B1 (en) 2020-01-01
HRP20200351T1 (hr) 2020-06-12

Similar Documents

Publication Publication Date Title
BR112015016817A8 (pt) métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
CR20180034A (es) Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112016010169A2 (pt) anticorpos anticlaudina e métodos de uso
BR112018068461A2 (pt) conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
BR112015027322A8 (pt) Compostos antissenso conjugados e sua utilização
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112016016580A2 (pt) Polissacarídeos capsulares de streptococcus pneumoniae e conjugados dos mesmos
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
EP3471771A4 (en) ANTIBODY CONJUGATES HAVING AMATOXIN DERIVATIVES AS A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/00 (2006.01), C08B 37/00 (2006.01), A61K 4

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2014, OBSERVADAS AS CONDICOES LEGAIS.